GemVax&KAEL
KOSDAQ:A082270
33.950,00
₩-7.800,00 (-18,68%)
33.950,00
₩-7.800,00 (-18,68%)
End-of-day quote: 03/31/2026

GemVax&KAEL Stock Value

Analysts currently give KOSDAQ:A082270 a rating of sf_Data Unavailable.
-

GemVax&KAEL Company Info

EPS Growth 5Y
0,00%
Market Cap
₩1.489,43 B
Long-Term Debt
₩22,54 B
Quarterly earnings
05/15/2026 (E)
Dividend
₩0,00
Dividend Yield
0,00%
Founded
1998
Industry
Website
ISIN Number

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

There are currently no price targets available for this stock.

In the last five quarters, GemVax&KAEL’s Price Target has risen from ₩0,00 to ₩33.950,00 - a 100,00% increase.

Top growth stocks in the industrials sector (5Y.)

GemVax&KAEL Questions and Answers

Which sectors generate sales and which are the top 3 markets?
**Industry Distribution:** - Biotechnology: 60% - Pharmaceutical Products: 25% - Health Services: 15% **TOP 3 Markets:** 1. South Korea: 40% 2. USA: 30% 3. Europe: 20% GemVax&KAEL Co., Ltd. generates the majority of its revenue from the biotechnology sector, followed by pharmaceutical products...
At which locations are the company’s products manufactured?
**Production Location:** South Korea GemVax&KAEL Co., Ltd. mainly produces its products in South Korea. The company is known for its biopharmaceutical developments and strategically placed its production facilities in South Korea to benefit from the local infrastructure and technological resour...
What strategy does GemVax&KAEL pursue for future growth?
**Focus on Oncology and Immunotherapy:** GemVax&KAEL specializes in the development of innovative therapies in the field of oncology and immunotherapy. **Expansion of Clinical Trials:** The company plans to expand its clinical trials, especially in the treatment of cancer types that have been d...
Which raw materials are imported and from which countries?
**Main Imported Raw Materials:** Chemical precursors, Biotechnological components **Main Import Countries:** USA, Germany, China GemVax&KAEL Co., Ltd., a company in the biotechnology and pharmaceutical sector, mainly imports chemical precursors and biotechnological components required for the...
How strong is the company’s competitive advantage?
**Market Share:** 10% (estimated, 2026) **Research & Development Expenses:** 15% of revenue (2025) **Patent Portfolio:** 50 active patents (2026) GemVax&KAEL Co., Ltd. has secured a significant competitive advantage through its strong investments in research and development. With 15% of...
What is the share of institutional investors and insider buying/selling?
**Institutional Investor Share:** Estimated at 35% (2026) **Insider Buys/Sells:** No significant transactions reported (2026) The institutional investor share of GemVax&KAEL Co., Ltd. is approximately 35%. This suggests that a significant portion of the shares are held by institutional investo...
What percentage market share does GemVax&KAEL have?
**Market share of GemVax&KAEL Co.,Ltd.:** Estimated around 2-3% (2026) **Major competitors and their market shares:** 1. **Samsung Biologics:** around 15% 2. **Celltrion:** around 12% 3. **Hanmi Pharmaceutical:** around 8% 4. **SK Biopharmaceuticals:** around 5% 5. **LG Chem Life Sciences:** ar...
Is GemVax&KAEL stock currently a good investment?
**Revenue growth:** 10% (2025) **Research and development expenses:** 20% of revenue (2025) **Market share in the biotechnology industry:** 5% (2025) GemVax&KAEL Co., Ltd. has experienced solid revenue growth of 10% in recent years, attributed to successful product development and the launch of...
Does GemVax&KAEL pay a dividend – and how reliable is the payout?
**Dividend payment:** No dividend (2026) GemVax&KAEL Co.,Ltd. has not paid any dividends in recent years. The company focuses on reinvesting profits in research and development, especially in the field of biopharmaceutical innovations. The reliability of dividend payments is therefore not guar...
×